Latest / Health and life sciences

Isomorphic Labs raises $2.1bn for its AI drug-design engine

DealHealthScienceGBConfirmed

Alphabet's DeepMind spin-out Isomorphic Labs raised $2.1 billion led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund, to scale its IsoDDE drug-design engine and pipeline. CEO Demis Hassabis had said in January that first clinical trials were now expected by end-2026, a year later than his earlier target.

Why it matters

It is among the largest bets yet that AI can shorten drug discovery, though the company still has no drug in human trials.

SourceIsomorphic LabsCoverage: Reuters (via WHTC)Coverage: Investing.com (Reuters) Checked against the primary source. Independently fact-checked on 7 Oct 2026.
Isomorphic LabsGoogle DeepMindGoogleThrive Capital

Line of Thought

Follow this story

Pick any item to keep going. Your path builds up above as a line you can share.

Directly linked

Connections our researchers recorded

What led here

Earlier developments on the same thread

What happened next

Later developments on the same thread

Same story elsewhere

What other countries and bodies did on this

Threads by topic: Drug discovery Investment and financing Biology